Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-F3083 in Type 2 Diabetes Mellitus
NCT03986073Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TQ-F3083 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Glycosylated hemoglobin at 15 weeks. Status: unknown.
02
Drugs
TQ-F3083
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03986073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03986073.